Literature DB >> 31864549

The Evolving Landscape of Resistance to Osimertinib.

Adam J Schoenfeld1, Helena A Yu2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31864549     DOI： 10.1016/j.jtho.2019.11.005

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  12 in total

1.  Acquired EGFR C797G Mutation Detected by Liquid Biopsy as Resistance Mechanism After Treatment With Osimertinib: A Case Report.

Authors:  Elisa DE Carlo; Monica Schiappacassi; Giacomo Pelizzari; Tania Baresic; Alessandro Del Conte; Brigida Stanzione; Valentina DA Ros; Roberto Doliana; Gustavo Baldassarre; Alessandra Bearz
Journal:  In Vivo       Date:  2021 Sep-Oct       Impact factor: 2.155

Review 2.  Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?

Authors:  Elisa Bertoli; Elisa De Carlo; Alessandro Del Conte; Brigida Stanzione; Alberto Revelant; Kelly Fassetta; Michele Spina; Alessandra Bearz
Journal:  Int J Mol Sci       Date:  2022-06-22       Impact factor: 6.208

3.  Results of a worldwide external quality assessment of cfDNA testing in lung Cancer.

Authors:  Jennifer A Fairley; Melanie H Cheetham; Simon J Patton; Etienne Rouleau; Marc Denis; Elisabeth M C Dequeker; Ed Schuuring; Kaat van Casteren; Francesca Fenizia; Nicola Normanno; Zandra C Deans
Journal:  BMC Cancer       Date:  2022-07-12       Impact factor: 4.638

Review 4.  Toward personalized treatment approaches for non-small-cell lung cancer.

Authors:  Meina Wang; Roy S Herbst; Chris Boshoff
Journal:  Nat Med       Date:  2021-08-12       Impact factor: 87.241

5.  Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.

Authors:  Xiao-Feng Li; Wei-Zhang Shen; Xin Jin; Ping Ren; Jie Zhang
Journal:  Sci Rep       Date:  2020-07-08       Impact factor: 4.379

6.  HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs.

Authors:  Sho Watanabe; Yasushi Goto; Hiroyuki Yasuda; Takashi Kohno; Noriko Motoi; Yuichiro Ohe; Hiroyoshi Nishikawa; Susumu S Kobayashi; Kazuyoshi Kuwano; Yosuke Togashi
Journal:  Thorac Cancer       Date:  2021-01-20       Impact factor: 3.500

7.  An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer.

Authors:  Yuexiao Qi; Xiaojun Xia; Lihua Shao; Liyun Guo; Yumei Dong; Jinhui Tian; Lijun Xu; Ruijun Niu; Shihong Wei
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

Review 8.  Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?

Authors:  Laura Bonanno; Alessandro Dal Maso; Alberto Pavan; Elisabetta Zulato; Lorenzo Calvetti; Giulia Pasello; Valentina Guarneri; PierFranco Conte; Stefano Indraccolo
Journal:  Br J Cancer       Date:  2022-03-09       Impact factor: 9.075

9.  Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer.

Authors:  Xiaoke Liu; Lingzhi Hong; Monique Nilsson; Shawna Marie Hubert; Shuhong Wu; Waree Rinsurongkawong; Jeffery Lewis; Amy Spelman; Jack Roth; Steven Swisher; Yong He; J Jack Lee; Bingliang Fang; John V Heymach; Jianjun Zhang; Xiuning Le
Journal:  Lung Cancer       Date:  2020-09-09       Impact factor: 5.705

10.  Pilot Study of Dacomitinib for Patients With Metastatic EGFR-Mutant Lung Cancers With Disease Progression After Initial Treatment With Osimertinib.

Authors:  Noura J Choudhury; Alex Makhnin; Yosef Y Tobi; Robert M Daly; Isabel R Preeshagul; Afsheen N Iqbal; Linda S Ahn; Sara A Hayes; Glenn Heller; Mark G Kris; Gregory J Riely; Helena A Yu
Journal:  JCO Precis Oncol       Date:  2021-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.